April 24, 2026 AlzeCure Pharma carries out a fully secured rights issue of approximately SEK 30.1 million
April 20, 2026 Last patient has completed AlzeCure’s Phase Ib clinical study with NeuroRestore ACD856
March 19, 2026 AlzeCure presents new preclinical data with NeuroRestore ACD856 at the Alzheimer’s Conference AD/PD
February 3, 2026 AlzeCure abstract on NeuroRestore ACD856 accepted at the Alzheimer’s conference AP/PD 2026
